Unrecognized ingestion of Toxoplasma gondii oocysts leads to congenital toxoplasmosis and causes epidemics in North America.

BACKGROUND Congenital toxoplasmosis presents as severe, life-altering disease in North America. If mothers of infants with congenital toxoplasmosis could be identified by risks, it would provide strong support for educating pregnant women about risks, to eliminate this disease. Conversely, if not all risks are identifiable, undetectable risks are suggested. A new test detecting antibodies to sporozoites demonstrated that oocysts were the predominant source of Toxoplasma gondii infection in 4 North American epidemics and in mothers of children in the National Collaborative Chicago-based Congenital Toxoplasmosis Study (NCCCTS). This novel test offered the opportunity to determine whether risk factors or demographic characteristics could identify mothers infected with oocysts. METHODS Acutely infected mothers and their congenitally infected infants were evaluated, including in-person interviews concerning risks and evaluation of perinatal maternal serum samples. RESULTS Fifty-nine (78%) of 76 mothers of congenitally infected infants in NCCCTS had primary infection with oocysts. Only 49% of these mothers identified significant risk factors for sporozoite acquisition. Socioeconomic status, hometown size, maternal clinical presentations, and ethnicity were not reliable predictors. CONCLUSIONS Undetected contamination of food and water by oocysts frequently causes human infections in North America. Risks are often unrecognized by those infected. Demographic characteristics did not identify oocyst infections. Thus, although education programs describing hygienic measures may be beneficial, they will not suffice to prevent the suffering and economic consequences associated with congenital toxoplasmosis. Only a vaccine or implementation of systematic serologic testing of pregnant women and newborns, followed by treatment, will prevent most congenital toxoplasmosis in North America.

[1]  D. Hill,et al.  Identification of a Sporozoite-Specific Antigen from Toxoplasma gondii , 2011, The Journal of parasitology.

[2]  R. McLeod,et al.  Clinical Manifestations of Ocular Toxoplasmosis , 2011, Ocular immunology and inflammation.

[3]  A. Montpetit,et al.  NALP1 Influences Susceptibility to Human Congenital Toxoplasmosis, Proinflammatory Cytokine Response, and Fate of Toxoplasma gondii-Infected Monocytic Cells , 2010, Infection and Immunity.

[4]  J. Blackwell,et al.  P2X7 Receptor-Mediated Killing of an Intracellular Parasite, Toxoplasma gondii, by Human and Murine Macrophages , 2010, The Journal of Immunology.

[5]  J. Blackwell,et al.  Host genetic and epigenetic factors in toxoplasmosis. , 2009, Memorias do Instituto Oswaldo Cruz.

[6]  R. McLeod,et al.  Why prevent, diagnose and treat congenital toxoplasmosis? , 2009, Memorias do Instituto Oswaldo Cruz.

[7]  Annie F Kuo,et al.  Longitudinal study of new eye lesions in children with toxoplasmosis who were not treated during the first year of life. , 2008, American journal of ophthalmology.

[8]  R. McLeod,et al.  Toxoplasmosis-associated neovascular lesions treated successfully with ranibizumab and antiparasitic therapy. , 2008, Archives of ophthalmology.

[9]  Martine Wallon,et al.  Genetic and Epigenetic Factors at COL2A1 and ABCA4 Influence Clinical Outcome in Congenital Toxoplasmosis , 2008, PloS one.

[10]  Annie F Kuo,et al.  Longitudinal study of new eye lesions in treated congenital toxoplasmosis. , 2008, Ophthalmology.

[11]  R. McLeod,et al.  Cataracts in congenital toxoplasmosis. , 2007, Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus.

[12]  R. McLeod,et al.  Impact of Visual Impairment on Measures of Cognitive Function for Children With Congenital Toxoplasmosis: Implications for Compensatory Intervention Strategies , 2006, Pediatrics.

[13]  R. McLeod,et al.  Outcome of treatment for congenital toxoplasmosis, 1981-2004: the National Collaborative Chicago-Based, Congenital Toxoplasmosis Study. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  D. Hill,et al.  Biology and epidemiology of Toxoplasma gondii in man and animals , 2005, Animal Health Research Reviews.

[15]  J. Levy,et al.  Humane strategies for controlling feral cat populations. , 2004, Journal of the American Veterinary Medical Association.

[16]  J. Shenai,et al.  Infectious Diseases of the Fetus and Newborn Infant , 2001, Journal of Perinatology.

[17]  F. Roberts,et al.  HLA-class II genes modify outcome of Toxoplasma gondii infection. , 1999, International journal for parasitology.

[18]  J. Isaac-Renton,et al.  Multiple cases of acquired toxoplasmosis retinitis presenting in an outbreak. , 1998, Ophthalmology.

[19]  R. McLeod,et al.  Resolution of intracranial calcifications in infants with treated congenital toxoplasmosis. , 1996, Radiology.

[20]  N. Roizen,et al.  Early and longitudinal evaluations of treated infants and children and untreated historical patients with congenital toxoplasmosis: the Chicago Collaborative Treatment Trial. , 1994, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  R. McLeod,et al.  Levels of pyrimethamine in sera and cerebrospinal and ventricular fluids from infants treated for congenital toxoplasmosis. Toxoplasmosis Study Group , 1992, Antimicrobial Agents and Chemotherapy.

[22]  R. McLeod,et al.  Absence of Sensorineural Hearing Loss in Treated Infants and Children with Congenital Toxoplasmosis , 1992, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[23]  S. Teutsch,et al.  Epidemic toxoplasmosis associated with infected cats. , 1979, The New England journal of medicine.

[24]  J. K. Frenkel,et al.  Ocular toxoplasmosis; pathogenesis, diagnosis and treatment. , 1958, A.M.A. archives of ophthalmology.

[25]  F. Wilcoxon Individual Comparisons by Ranking Methods , 1945 .

[26]  E. Levine Risk factors for Toxoplasma gondii infection in mothers of infants with congenital toxoplasmosis: implications for prenatal management and screening. , 2006, American journal of obstetrics and gynecology.

[27]  R. McLeod,et al.  Eye manifestations of congenital toxoplasmosis. , 1996, American journal of ophthalmology.

[28]  R. McLeod,et al.  Neurologic and developmental outcome in treated congenital toxoplasmosis. , 1995, Pediatrics.

[29]  R. Dailly [ACQUIRED TOXOPLASMOSIS]. , 1964, La Presse medicale.

[30]  J. Couvreur,et al.  [Acquired toxoplasmosis. (Study of 227 cases)]. , 1960, Archives francaises de pediatrie.